Abstract:BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a malignant tumor with an extremely poor prognosis. Effective targets for anticancer therapy confirmed in PDAC are limited. However, the characteristics of genomics have not been fully elucidated in large-scale patients with PDAC from China.METHODS: We collected both blood and tissue samples from 1080 Chinese patients with pancreatic cancer and retrospectively investigated the genomic landscape using next-generation sequencing (NGS).FINDINGS: We found recurrent somatic mutations in KRAS (83.2%), TP53 (70.6%), CDKN2A (28.8%), SMAD4 (23.0%), ARID1A (12.8%) and CDKN2B (8.9%) in Chinese PDAC patients. Compared with primary pancreatic cancers, more genomic alterations accumulated especially cell cycle regulatory gene variants (45.4% vs 31.6%, P < 0.001) were observed in metastatic tumors. The most common mutation site of KRAS is p.G12D (43.6%) in pancreatic cancer. Patients with KRAS mutations were significantly associated with older age and mutations in the other three driver genes, while KRAS wild-type patients contained more fusion mutations and alternative mechanisms of RTK/Ras/MAPK pathway including a number of clinically targetable mutations. KRAS mutations in Chinese cohort were significantly lower than those in Western cohorts (all P < 0.05). A total of 252 (23.3%) patients with the core DNA damage response (DDR) gene mutations were detected. ATM (n =59, 5.5%) was the most frequent mutant DDR gene in patients with pancreatic cancer from China. Patients with germline DDR gene mutations were younger (P = 0.018), while patients with somatic DDR gene mutations were more likely to accumulate in metastatic lesions (P < 0.001) and had higher TMB levels (P < 0.001). In addition, patients with mutant DDR genes and patients carrying TP53 mutation were observed mutually exclusive (P < 0.001).INTERPRETATION: We demonstrated the real-world genomic characteristics of large-scale patients with pancreatic cancer from China which may have promising implications for further clinical significance and drug development.FUNDING: The funders are listed in the Acknowledgement.

YAP 1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma

YAP1 Oncogene is a Context-Specific Driver for Pancreatic Ductal Adenocarcinoma

YAP1 Mediates Gastric Adenocarcinoma Peritoneal Metastases That Are Attenuated by YAP1 Inhibition.

Effect of the transcription factor YY1 on the development of pancreatic endocrine and exocrine tumors: a narrative review

YAP in pancreatic cancer: oncogenic role and therapeutic strategy

Yes-associated protein (YAP) in pancreatic cancer: at the epicenter of a targetable signaling network associated with patient survival

The YAP1-NMU Axis Is Associated with Pancreatic Cancer Progression and Poor Outcome: Identification of a Novel Diagnostic Biomarker and Therapeutic Target

YY1 Targets Tubulin Polymerisation-Promoting Protein to Inhibit Migration, Invasion and Angiogenesis in Pancreatic Cancer Via P38/mapk and PI3K/AKT Pathways

YAP is a Critical Oncogene in Human Cholangiocarcinoma

Active YAP promotes pancreatic cancer cell motility, invasion and tumorigenesis in a mitotic phosphorylation-dependent manner through LPAR3

Inhibiting YAP Expression Suppresses Pancreatic Cancer Progression by Disrupting Tumor-Stromal Interactions

ENO1 contributes to the gemcitabine resistance of pancreatic cancer through the YAP1 signaling pathway

Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma

Proteogenomic insights into the biology and treatment of pancreatic ductal adenocarcinoma

The Prognostic Value of YAP1 on Clinical Outcomes in Human Cancers

Gene Regulation Network of Prognostic Biomarker YAP1 in Human Cancers: An Integrated Bioinformatics Study

YAP1-mediated Pancreatic Stellate Cell Activation Inhibits Pancreatic Cancer Cell Proliferation

YAP‐LAMB3 axis dictates cellular resistance of pancreatic ductal adenocarcinoma cells to gemcitabine

YAP1 status defines two intrinsic subtypes of LCNEC with distinct molecular features and therapeutic vulnerabilities

Proteogenomic characterization of pancreatic ductal adenocarcinoma

Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer